Board summary
Key figures
49,239
Registered population
61.1% aged 18–64
18.0%
Aged 65+
ICB 14.9% · England 17.9%
40.4%
In IMD quintile 1
ICB 40.7% · England 21.0%
~18,654
Core20 residents (est.)
Resident basis; registered basis ~19,928 · see page 3
8,186
Hypertension register
+10.90% in 3 yrs · England +5.60%
544
SMI register
15.2% of Wigan (LAD)'s
1,362
COPD register
Reviews -5.06% in 3 yrs
Forecast to 2030
10,363
Hypertension patients, 2030
+2,177 on today
82.6%
QRISK ≥20% on statins, 2030
+6.99pp over 3 yrs
4.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma review coverage fell below comparators.
Coverage reached 54.2% (England 65.7%) after a -7.1% three-year change (England +4.4%), leaving about 1,600 patients without a recorded review.
COPD reviews declined despite register growth.
Annual reviews reached 65.0% (England 76.4%) after a -5.1% three-year change, while COPD prevalence grew +12.1% to 2.8%.
Non-frail diabetes HbA1c control outpaced England.
Non-frail diabetes HbA1c control at or below 58 mmol/mol grew +14.0% over 2023 to 2025 (England +4.4%), reaching 61.0% (England 57.4%).
Population, age and ethnicity
Hindley PCN serves 49,239 registered patients, with 10,285 aged 0–17 and 8,867 aged 65+
Hindley PCN has 49,239 registered patients. Cohorts aged 0–17 represent 20.9% (10,285 patients), against 20.0% in Wigan (LAD), 21.8% in NHS Greater Manchester Integrated Care Board, and 19.6% in England. Patients aged 65+ comprise 18.0% (8,867 patients), against 18.8% in Wigan (LAD), 14.9% in the ICB, and 17.9% in England. Roma residents make up 0.1% (LAD 0.1%, ICB 0.1%, England 0.2%) and Gypsy or Irish Traveller residents 0.1% (0.1% across all comparators). Growth to 2030 is projected at 1.4% (LAD 1.1%, ICB 1.6%, England 2.3%), though projection methodology is unverified and observation periods are not supplied.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Wigan (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Wigan LA) | 2,706 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 83.7% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 61.0% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Wigan LA) | 1,243 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Wigan LA) | 12.3 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 patients make up 40.4% of Hindley PCN, spanning 52.5 pp across practices
Hindley PCN has an average IMD decile of 3.6, below Wigan (5.0), NHS Greater Manchester ICB (4.5), and England (5.5). Registered Core20 prevalence is 40.4%, above Wigan (29.4%), in line with the ICB (40.7%), and above England (21.0%). Across practices, Core20 shares span 52.5 pp from Dr Tun & Partners (25.6%) to Ince Surgery (78.2%, 6,426 estimated patients). Pennygate Medical Centre holds 5,539 estimated patients at a 28.7% share. Resident Core20 estimates (18,654) and practice registered estimates use different population bases.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
544
SMI register
1.11% recorded prevalence
363
Learning disability register
0.74% recorded prevalence
11
Care homes, 481 beds
In the PCN catchment
10.1%
Provide unpaid care
Wigan (LAD), Census 2021
The PCN records 363 learning disability patients (0.7%, England 0.6%) and 544 severe mental illness patients (1.1%, England 1.0%), alongside 11 catchment care homes with 481 beds. Borough context shows 11 rough sleepers and a 10.1% unpaid care rate; these cannot be extrapolated locally.
Severe mental illness: physical health checks
SMI prevalence is 1.1%. Blood pressure checks for SMI patients reached 79.1%, trailing England (83.4%) and Wigan (LAD) (84.1%), alongside recorded BMI at 81.3% (England 82.1%). Routine cardiovascular monitoring for severe mental illness patients remains below benchmark levels.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,186
Hypertension register
+10.90%
Register growth, 3 yrs
Wigan (LAD) +10.59% · England +5.60%
+3.79pp
BP control, under 80
≤140/90 · +5.47pp aged 80+
+2,177
More patients by 2030
Forecast 10,363 (20.49%)
Hypertension case-finding and control
Hypertension QOF prevalence is 16.7% (8,186 patients), below Wigan (18.0%) but above NHS Greater Manchester ICB (14.4%) and England (15.2%), with +10.9% three-year growth (Wigan +10.6%, ICB +5.6%, England +5.6%). Blood pressure treated to target is 72.8%, trailing Wigan (75.6%) but exceeding the ICB (71.4%) and England (70.3%), while 91.1% had a recent reading (Wigan 91.8%, ICB 90.3%, England 90.0%). Crude rates are not age-adjusted, yielding a register gap range of -687 to +698 patients.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy reached 66.0% (Wigan 64.0%, ICB 67.0%, England 63.6%). However, primary-prevention statin initiation in diabetes without CVD is 70.8%, trailing Wigan (72.5%), the ICB (75.7%), and England (73.2%).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 89,002 | £2.10 | £1.94 | £1.86 | £186,904 |
| Cardiovascular (all), 2025 | 127,109 | £4.47 | £3.15 | £3.33 | £568,177 |
For lipid-regulating drugs (2026 capture), the PCN prescribed 89,002 items at £2.10 per item, above Wigan (£2.09), the ICB (£1.94), and England (£1.86), totalling £186,904 in spend. Across these 89,002 items, this was £21,360 more than at England's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−7.13%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+0.97%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 7.6% (3,517 patients) and COPD prevalence is 2.8% (1,362 patients), with COPD prevalence growing +12.1% over 2023 to 2025 (England +2.6%). Over the same period, annual reviews fell 7.1% for asthma to 54.2% (England +4.4% to 65.7%), leaving about 1,600 patients without a recorded review, and fell 5.1% for COPD to 65.0% (England +2.8% to 76.4%). Asthma items in ages 5-19 reached 2,615 per 1,000 (England 1,488). Local audit would test whether falling review rates reflect recall capacity.
Cancer register and children's immunisation
Cancer prevalence is 3.6% (1,752 patients), trailing England (3.8%) and Wigan (LAD) (4.0%). In Q1 2025/26, 12-month 6-in-1 coverage reached 86.5% across 148 children, falling 8.5 pp below the 95.0% target. Across Hindley PCN, age-5 MMR coverage drops 3.5 pp between dose 1 (94.4%) and dose 2 (90.9%).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of staged cancers (6,491 of 11,679) across NHS Greater Manchester ICB were diagnosed at stage 1 or 2 (England 55.3%), below the 75.0% national ambition by 2028; staging was known for 70.8% of registrations (11,679 of 16,492). Staging reflects ICB-level data rather than PCN performance. Across Hindley PCN, cervical screening coverage in women aged 25 to 49 is 68.8% (England 66.8%, Wigan (LAD) 73.0%), with 60.5% at Rivington Way Surgery, 64.1% at Dr Tun & Partners, and 64.3% at Ince Surgery. Breast screening coverage stands at 73.9% (England 69.9%). Prioritising cervical screening outreach in lower-coverage practices offers an immediate primary care opportunity to support earlier detection.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
For Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust in Jul 2026 (provisional), the 62-day cancer referral to treatment standard reached 76.8%, below the 85.0% standard, but ahead of Bolton NHS Foundation Trust (69.7%), NHS Greater Manchester Integrated Care Board (75.7%), and England (71.2%), while trailing Mersey and West Lancashire Teaching Hospitals NHS Trust (78.0%). The trust achieved 82.8% on the 28-day faster diagnosis standard (standard 75.0%). In Jul 2026, diagnostic 6+ week waits were 0.0% for cystoscopy and 0.5% for MRI (England 21.4%). These figures reflect provider performance rather than PCN delivery.
| Pathways within standard (%) | Wrightington, Wigan and Leigh | Bolton | Mersey and West Lancashire | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 82.80 | 80.48 | 72.39 | 79.53 | 79.32 |
| 31-day treatment (96%) | 89.04 | 96.50 | 95.46 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 76.78 | 69.66 | 77.96 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Wrightington, Wigan and Leigh | Bolton | Mersey and West Lancashire | England |
|---|---|---|---|---|
| MRI | 0.49 | 2.05 | 14.04 | 21.40 |
| CT | 7.78 | 19.40 | 13.08 | 9.92 |
| Echocardiography | 24.37 | 3.48 | 34.88 | 28.48 |
| Colonoscopy | 6.10 | 1.33 | 18.04 | 30.83 |
| Gastroscopy | 12.54 | 2.06 | 18.17 | 29.02 |
| All 15 DM01 tests | 14.36 | 15.78 | 21.17 | 23.14 |
| Community services activity | Wigan residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 48,150 | 573,310 |
| Referrals | 13,750 | 94,470 |
| Patients with a contact | 18,695 | 183,535 |
Community services (residents of Wigan), Jun 2026 (provisional). In Jun 2026 (provisional), community health services recorded 48,150 contacts for borough residents, with 28,190 contacts for adults aged 65 and over (58.5% of contacts). This reflects borough-level resident activity rather than PCN delivery. Close primary care coordination with community teams remains important for older patients navigating diagnostic pathways.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, overall QOF achievement ranged from 73.2% at Dr Tun & Partners to 95.1% at Dr Ahmad & Ptnrs. Vaccination and immunisation achievement showed a 64.7 pp spread, from 19.2% at Rivington Way Surgery to 83.9% at Dr Tun & Partners, while personalised care adjustment rates reached 16.6% at Ince Surgery.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Platt House | 109 | 34.6 | 90.4% | 70.8% | 90.9% |
| Dr Ahmad & Ptnrs | 99 | 34.4 | 76.5% | 70.3% | 90.5% |
| Pennygate | 113 | 28.7 | 58.9% | 81.3% | 86.1% |
| Ince Surgery | 122 | 78.2 | 54.8% | 69.3% | 77.9% |
| Rivington Way | 102 | 63.3 | 56.0% | 75.1% | 69.5% |
| Dr Tun & Partners | 99 | 25.6 | 62.5% | 39.9% | 66.3% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Asthma review coverage changed -7.1% over three years while diabetes control rose +14.0%
Three-year relative changes trail England most in annual reviews for asthma (-7.1% vs England +4.4%) and COPD (-5.1% vs England +2.8%), alongside slower register growth in learning disability (+1.4% vs England +5.4%). Current levels also lag England in severe mental illness blood pressure checks (79.1% vs England 83.4%) and smoking cessation offers (89.8% vs England 94.2%). Conversely, the PCN outpaced England in three-year relative gains for non-frail diabetes HbA1c control (+14.0% to 61.0% vs England 57.4%), heart failure reviews (+15.8% to 74.4%), and QRISK at or above 20% lipid therapy (+11.8% to 66.0%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Asthma reviews
COPD reviews
Learning disability register
Alcohol record (psychosis)
Breast screening (53-70)
Diabetes HbA1c control
Heart failure reviews
QRISK statin treatment
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Wigan (LAD) | Asset | PCN | Wigan (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 11 (481 beds) | n/a | Schools (catchment) | 52 | n/a |
| Children's centres | 3 | 20 | Places of worship | 28 | 164 |
| Libraries | 1 | 10 | Primary schools (LA maintained) | 13 | 68 |
| Primary academies | 4 | 21 | Special schools | 1 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review recall
Asthma review coverage is 54.2% (Wigan (LAD) 64.4%, ICB 66.2%, England 65.7%) after a -7.1% 3-year change (England +4.4%), leaving 1,609 of 3,517 patients without a recorded review. For discussion, the PCN could run structured asthma recall using a single template and after-school slots alongside inhaler prescribing checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Hypertension detection and target titration
Hypertension prevalence is 16.7% (8,186 of 49,239 patients; Wigan (LAD) 18.0%, England 15.2%), giving a non-age-adjusted gap range of -687 to +698; BP control is 72.8% (Wigan (LAD) 75.6%). For discussion, practices could search for uncoded raised BP readings and run pharmacist-led titration reviews for patients above threshold. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
COPD annual review recovery
COPD annual review coverage is 65.0%, below Wigan (LAD) (76.7%), the ICB (76.4%), and England (76.4%), falling 5.1% over 2023 to 2025 (England +2.8%) across 1,362 registered patients (2.8%). For discussion, practices could align annual COPD review recall with seasonal vaccination contacts and review spirometry access with system partners. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Care home visiting capacity review (p2) | Count of care home beds in PCN catchment | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework: revenue finance and contracting guidance 2026 | PCN |
| Two-track Core20 resourcing (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI blood pressure recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension case finding and titration (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Childhood immunisation recall audit (p6) | 6-in-1 coverage at 12 months | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening uptake outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · Asthma management items prescribed per 1000 5-19 Population | Core20PLUS5 respiratory | PCN |
| Option 2 · Hypertension detection and target titration (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · COPD annual review recovery (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
